Omeros (NASDAQ:OMER) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Omeros (NASDAQ:OMER) in a report released on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $9.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Omeros has a consensus rating of “Hold” and an average target price of $9.00.

Omeros Stock Performance

Shares of OMER opened at $6.75 on Thursday. The stock has a market capitalization of $391.16 million, a P/E ratio of -2.92 and a beta of 1.47. The company’s fifty day moving average is $4.14 and its two-hundred day moving average is $4.11. Omeros has a 1 year low of $1.38 and a 1 year high of $7.51.

Hedge Funds Weigh In On Omeros

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its stake in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. MML Investors Services LLC grew its stake in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the period. SPC Financial Inc. purchased a new stake in shares of Omeros in the 3rd quarter worth about $77,000. SG Americas Securities LLC purchased a new stake in shares of Omeros in the 3rd quarter worth about $80,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Omeros in the 1st quarter worth about $85,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.